Date: 2016-02-08
Type of information: Nomination
Compound:
Company: Global Blood Therapeutics (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases - Hematological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On February 8, 2016, Global Blood Therapeutics announced the appointment of Mike Bonney, partner at Third Rock Ventures, and Glenn Pierce, M.D., Ph.D., formerly chief medical officer at Biogen, to its Board of Directors. The company also announced that Kevin Starr, partner at Third Rock Ventures, will retire from the Board after four years of membership. Mr. Bonney currently serves as a partner at Third Rock Ventures. He focuses on the formation, development and strategy for new portfolio companies. Previously, he served as chief executive officer and a member of the Board of Directors of Cubist Pharmaceuticals. Prior to that, he held various positions of increasing responsibility at Biogen, including vice president, sales and marketing, and at Zeneca Pharmaceuticals, where he held positions in sales, marketing and strategic planning. Mr. Bonney currently serves as chairman of the Board of Directors for Alnylam Pharmaceutical, and as a Board member for Celgene, the Whitehead Institute for Biomedical Research, and the Gulf of Maine Research Institute. He was a director of NPS Pharmaceuticals until its sale to Shire in February 2015. He is also a trustee of the Tekla complex of life sciences and healthcare dedicated funds, which include the H&Q Healthcare Investors and H&Q Life Sciences Investors funds. He was a member of Pharmaceutical Research and Manufacturers of America (PhRMA) from 2009-2014 and Biotechnology Innovation Organization (BIO). He earned a B.A. in economics from Bates College, where he now serves as chairman of the Board of Trustees. Dr. Pierce retired from Biogen in 2014, where he served in various roles including as chief medical officer for hematology, and as head of global medical affairs, and most recently led the Hematology, Cell and Gene Therapies division. He had overall R&D responsibility for hemophilia and hemoglobinopathies and led the research and clinical development of extended half-life FVIII and FIX Fc fusions, which culminated in multiple regulatory approvals in 2014. He is the co-author of more than 150 scientific papers and has over 15 patents. He is a member of numerous medical and scientific groups including the Hemostasis & Thrombosis Research Society (HTRS), the International Society on Thrombosis and Haemostasis (ISTH) and the American Society of Hematology (ASH). He currently serves on the World Federation of Hemophilia (WFH) and WFHUSA Board of Directors and on the National Hemophilia Foundation (NHF) (U.S.) Medical and Scientific Advisory Council. Previously, he served as president of the Board of the NHF (U.S.). He also served on the U.S. Food and Drug Administration’s (FDA) Blood Products Advisory Committee and the U.S. Department of Health and Human Services’ Committee on Blood Safety and Availability. Dr. Pierce received an M.D. and a Ph.D. in immunology from Case Western Reserve University in Cleveland and his postgraduate training in pathology and hematology research at Washington University in St. Louis.
Financial terms:
Latest news:
